HIV and Hepatitis B Coinfection Among Perinatally HIV-infected Thai Adolescents
Authors:
- Pope KosalaraksaPKPope Kosalaraksa
- Yong PoovorawanYPYong Poovorawan
- Thanyawee PuthanakitTPThanyawee Puthanakit
- 1 September 2012
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 31 (9) , 943-947
Abstract
Objectives: This study aimed to determine the prevalence of hepatitis B virus (HBV) coinfection and HBV seropositivity in perinatally HIV-infected adolescents. A secondary objective was to describe the clinical characteristics of adolescents with chronic HBV/HIV coinfection. Materials and Methods: Multicenter cross-sectional study of perinatally HIV-infected adolescents aged 12–25 years. HBV surface antigen, surface antibody (anti-HBs) and core antibody (anti-HBc) were measured. Coinfection was defined as having persistently positive HBV surface antigen. Seroprotective antibody from immunization was defined as having anti-HBs ≥10 mIU/mL with negative anti-HBc. HBV DNA quantitation and rtM204V/I mutation analysis (lamivudine resistance–associated mutation) were performed in adolescents with chronic HBV infection. Results: From November 2010 to March 2011, 521 patients were enrolled. Mean (SD) of CD4 lymphocyte count was 685 (324) cells/μL. The prevalence of HBV/HIV coinfection was 3.3% (95% confidence interval: 1.9–5.2%). Protective antibody against HBV was found in 18% of population, and this was significantly higher among adolescents who received than those who did not receive HBV revaccination after receiving antiretroviral therapy (93% versus 6%, P < 0.01). Among adolescents with chronic HBV infection, 88% have received lamivudine; however, 69% have HBV DNA >105 copies/mL and 75% had the rtM204V/I mutation. Conclusions: The prevalence of HBV coinfection in HIV-infected Thai adolescents was 3.3%. Most HIV-infected adolescents had no HBV protective antibody; therefore, revaccination with HBV vaccine is encouraged. The high prevalence of HBV-lamivudine resistance underscores the importance of HBV screening prior to antiretroviral therapy initiation to guide the selection of optimal regimen for coinfected children.Keywords
This publication has 24 references indexed in Scilit:
- Factors associated with isolated anti-hepatitis B core antibody in HIV-positive patients: impact of compromised immunityJournal of Viral Hepatitis, 2009
- Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY)AIDS, 2007
- Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunizationTropical Medicine & International Health, 2006
- Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.2005
- Simultaneous quantitation and genotyping of hepatitis B virus by real-time PCR and melting curve analysisJournal of Virological Methods, 2004
- Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohortAIDS, 2004
- Isolated Antibody to Hepatitis B Core Antigen in Human Immunodeficiency Virus Type-1--Infected IndividualsClinical Infectious Diseases, 2003
- Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patientsHepatology, 1999
- What Level of Hepatitis B Antibody Is Protective?The Journal of Infectious Diseases, 1999
- Acute Hepatitis B Virus Infection: Relation of Age to the Clinical Expression of Disease and Subsequent Development of the Carrier StateThe Journal of Infectious Diseases, 1985